The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 29, 2022

Filed:

Mar. 27, 2019
Applicant:

Seoul National University R & Db Foundation, Seoul, KR;

Inventors:

Bum-Joon Kim, Seoul, KR;

Byoung-Jun Kim, Uiwang-Si, KR;

Bo-Ram Kim, Seoul, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/74 (2006.01); A61P 31/18 (2006.01); A61P 31/06 (2006.01); A61K 39/04 (2006.01); A61K 39/21 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/74 (2013.01); A61K 39/04 (2013.01); A61K 39/21 (2013.01); A61P 31/06 (2018.01); A61P 31/18 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/523 (2013.01); A61K 2039/70 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16034 (2013.01); C12N 2740/16071 (2013.01);
Abstract

Provided is a recombinant BCG employing a pMyong2 vector system to express HIV-1 p24 and a use thereof as a HIV-1 vaccine. rBCG-pMyong2-p24, which is a pMyong2 vector system, was found to induce the upregulation of HIV-1 p24 gag expression in rBCG and infected antigen-presenting cells (APC) and to induce improved p24-specific immune responses in vaccinated mice, compared to rBCG-pAL-p24 in a pAL5000 derived vector system. rBCG-pMyong2-p24 was identified to exhibit a higher p24-specific Ab production level than rSmeg-pMyong2-p24 in the same pMyong2 vector system. Therefore, the recombinant BCG employing rBCG-pMyong2-p24 to express HIV-1 p24 according to the present invention is identified to elicit enhanced immune responses to HIV-1 infection in mouse model systems and thus can be expected to be used as a prime vaccine in the heterologous prime-boost vaccination strategy against HIV-1 infection.


Find Patent Forward Citations

Loading…